Boehringer Inhgelheim has opened a new €120 million Respimat manufacturing facility in Sant Cugat del Vallés, Spain, near Barcelona, the company said. The 17,000 sq m plant is expected to produce 25 million units per year, over half of Respimat global annual sales. The facility will create approximately 200 new jobs. Boehringer Ingelheim Spain CEO Peter Ploeger … [Read more...] about Boehringer Ingelheim opens new Respimat manufacturing facility
News
Theravance and Mylan add China to nebulized revefenacin agreement
Theravance Biopharma and Mylan have expanded their 2015 development and commercialization agreement for nebulized revefenacin (formerly TD-4208) to include China, Hong Kong, Macau, and Taiwan. The 2015 agreement included all markets except for China and the additional territories that have now been added. Mylan will pay Theravance $18.5 million up front and up to … [Read more...] about Theravance and Mylan add China to nebulized revefenacin agreement
Upsher-Smith acquires US rights to Tosymra sumatriptan nasal spray
Upsher-Smith Laboratories has acquired the US rights to Tosymra sumatriptan nasal spray from Dr. Reddy's Laboratories, the companies have announced. The FDA approved Dr. Reddy's subsidiary Promius Pharma's NDA for Tosymra in January 2019. The agreement, which also covered US rights to Zembrace Symtouch sumatriptan injection, included a $70 million upfront payment, … [Read more...] about Upsher-Smith acquires US rights to Tosymra sumatriptan nasal spray
In Memoriam: Ola Nerbrink
Members of the OINDP community are remembering inhalation expert Ola Nerbrink, who passed away on June 1, 2019. He was the CEO of Respiron Consulting, which he founded in 2009, and VP of Business Development at the Medicon Valley Inhalation Consortium (MVIC), where he had served as CEO from 2014 to 2017. In 2017, he also took a position as Senior Sales Advisor for … [Read more...] about In Memoriam: Ola Nerbrink
Proveris Scientific adds Stephen McDonald to its European support team
Proveris Scientific announced that Stephen McDonald has joined the company's European team, which is based in the UK. McDonald, who has previously worked with Proveris to provide customer support as an independent contractor, will work with European Sales Director Deborah Jones providing customer service support for Europe and the Middle East. McDonald has more … [Read more...] about Proveris Scientific adds Stephen McDonald to its European support team
Phase 3 study of Molgradex inhaled GM-CSF for the treatment of aPAP fails to meet primary endpoint
Inhaled drug developer Savara has announced that the Phase 3 IMPALA study of Molgradex inhaled formulation recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP) failed to meet its primary endpoint, improvement in alveolar-arterial oxygen gradient (A-aDO2). The study … [Read more...] about Phase 3 study of Molgradex inhaled GM-CSF for the treatment of aPAP fails to meet primary endpoint
Dance Biopharm presents positive Phase 2 results for Dance 501 inhaled insulin
During the 2019 annual meeting of the American Diabetes Association (ADA), Dance Biopharm presented data from the Phase 2 Samba 04 clinical trial of Dance 501 inhaled insulin for the treatment of Type 2 diabetes demonstrating that Dance 501 had a more rapid onset of action than subcutaneous insulin lispro. The Samba 04 study enrolled 24 Type 2 patients who were … [Read more...] about Dance Biopharm presents positive Phase 2 results for Dance 501 inhaled insulin
Insys Therapeutics files for bankruptcy, plans to sell all assets
Insys Therapeutics has filed for Chapter 11 bankruptcy and plans to sell "substantially all of the company’s assets," the company said. Insys's pipeline includes inhaled dronabinol, intranasal epinephrine, and intranasal naloxone. NDA submissions for the nasal sprays had been planned for 2019. The bankruptcy filing comes in the wake of legal troubles related to … [Read more...] about Insys Therapeutics files for bankruptcy, plans to sell all assets
Aptar acquires Nanopharm and Gateway Analytical
AptarGroup has announced its acquisition of Nanopharm and Gateway Analytical as "part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments." The two companies were acquired by Aptar for a total of approximately $50 million. Both will continue to … [Read more...] about Aptar acquires Nanopharm and Gateway Analytical
Theravance Biopharma appoints Andrew Hindman as Senior VP and CFO
Theravance Biopharma has named former Acorda Therapeutics Chief Business Officer Andrew Hindman as Senior VP and Chief Financial Officer. Hindman, who led Acorda's acquisition of Inbrija inhaled L-dopa developer Civitas Therapeutics in 2014, also previously served as President and CEO of Tobira Therapeutics and held executive positions at Onyx Pharmaceuticals and … [Read more...] about Theravance Biopharma appoints Andrew Hindman as Senior VP and CFO